Mode
Text Size
Log in / Sign up
N/A Completed N=17,448

Outcomes for Medicare Asthma Patients Taking Fluticasone Propionate/Salmeterol Xinafoate Combination Versus Inhaled Corticosteroids or Other Combination Therapy

Source: ClinicalTrials.gov NCT01347060 ↗
Enrolled (actual)
17,448
Serious AEs
—
Results posted
Jun 2011
Primary outcomePrimary: Mean Number of Post-index Asthma-related Events Measured Using Medical and Pharmacy Claims — 0.033; 0.046; 0.022; 0.027 Asthma-related events — p=0.0051

Summary

The objective of this study is to compare healthcare utilization and costs in Medicare-eligible asthma patients (aged >65) who receive fluticasone propionate/salmeterol xinafoate combination or inhaled corticosteroids in a typical clinical practice using a retrospective observational cohort study design of large managed care database. Outcomes on interest include asthma related severe exacerbations defined as asthma related emergency department visits, hospitalizations or combined emergency department/hospitalization. Other outcomes of interest include use of albuterol, oral corticosteroids and overall asthma related costs. Outcomes of interest will be compared between the two treatment cohorts (fluticasone propionate/salmeterol xinafoate combination or inhaled corticosteroids). Dichotomous outcomes (emergency visits, hospitalizations etc) will be compared using Cox regression hazards analysis assessing time to first event for each asthma related endpoint adjusting for differences in baseline demographics such as age, gender, previous asthma medication use, co morbidities, costs, and plan demographics. Total asthma related costs will also be compared using generalized linear models adjusting for baseline differences.

Outcome Measures

OutcomeResultp-value
PRIMARY
Mean Number of Post-index Asthma-related Events Measured Using Medical and Pharmacy Claims
0.033; 0.046; 0.022; 0.027; 0.05; 0.07 0.0051 sig
SECONDARY
Mean Asthma-related Costs in the Post-index Period
381; 462; 1128; 939; 1509; 1401 0.001 sig
SECONDARY
Mean Number of Albuterol (Short-acting β-Agonists) Canisters Dispensed Per Pharmacy Claim Per Participant
1.01; 1.5 <0.0001 sig

Eligibility Criteria

Inclusion Criteria

  • Subjects with asthma as determined by ICD-9 codes and asthma drug use
  • at least 65 years of age
  • prescription for an inhaled corticosteroid

Exclusion Criteria

  • a diagnosis of chronic obstructive pulmonary disease or
  • a prescription for a chronic obstructive pulmonary disease treatment
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01347060). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search